REPLIMUNE GROUP INC (REPL)

US76029N1063 - Common Stock

6.44  -0.28 (-4.17%)

After market: 6.44 0 (0%)

News Image
3 days ago - InvestorPlace

REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024

REPL stock results show that Replimune Group missed analyst estimates for earnings per share the fourth quarter of 2024.

News Image
3 days ago - BusinessInsider

REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Replimune Group (NASDAQ:REPL) just reported results for the fourth quarter of 2...

News Image
4 days ago - Replimune Group Inc

Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update

Twelve-month primary analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) in anti-PD1 failed...

News Image
a month ago - Market News Video

Oversold Conditions For Replimune Group (REPL)

News Image
a month ago - Replimune Group Inc

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in...

News Image
2 months ago - Replimune Group Inc

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

News Image
2 months ago - Replimune Group Inc

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization ...

News Image
3 months ago - Seeking Alpha

Replimune Group GAAP EPS of -$0.77 beats by $0.16 (NASDAQ:REPL)

Replimune Group reported Q3 2024 financial results, beating expectations with a GAAP EPS of -$0.77.

News Image
3 months ago - Replimune Group Inc

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma demonstrating durability...

News Image
4 months ago - DISCO Pharmaceuticals

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets....

News Image
5 months ago - Replimune Group Inc

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development...

News Image
6 months ago - Market News Video

Oversold Conditions For Replimune Group (REPL)

News Image
6 months ago - InvestorPlace

Why Is Replimune (REPL) Stock Down 48% Today?

Replimune stock is dropping on Tuesday as investors in REPL shares react to a clinical trial missing both of its primary endpoints.

News Image
6 months ago - Seeking Alpha

Replimune shares crash as skin cancer candidate fails trial (NASDAQ:REPL)

Replimune shares plummeted after their RP1 candidate failed to meet primary endpoints in a trial for treating a type of skin cancer, causing concerns for...

News Image
6 months ago - Replimune Group Inc

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to...

News Image
6 months ago - Market News Video

Notable Monday Option Activity: REPL, HRT, ASC

News Image
6 months ago - Replimune Group Inc

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

RP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in nearly 30 percent of patients, all with...

News Image
6 months ago - Market News Video

Oversold Conditions For Replimune Group (REPL)

News Image
7 months ago - Market News Video

Notable Friday Option Activity: REPL, WDFC, PII

News Image
7 months ago - Market News Video

Replimune Group Enters Oversold Territory (REPL)

News Image
7 months ago - Market News Video

Notable Monday Option Activity: HZO, REPL, AVAV

News Image
8 months ago - Market News Video

Replimune Group is Now Oversold (REPL)

News Image
8 months ago - Replimune Group Inc

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...